Advertisement
Table 1 Descriptive statistics of the total group of patients who underwent RRSO (n = 471)
| Number | Percentage | Range | |
|---|---|---|---|
| Age (median, year) | 48 | % | 33–78 |
| Mutations | |||
| -BRCA1 | 288 | 61.1 | |
| -BRCA2 | 126 | 26.8 | |
| -BRCA1 and BRCA2 | 2 | 0.4 | |
| -HBOC | 55 | 11.7 | |
| CA-125 preoperative (n) | 466 | ||
| -median (U/ml) | 14.0 | 4.0–93.0 | |
| -elevated CA125 (>35 U/ml) (n) | 10 | 2.1 | |
| Surgical technique (n) | 471 | ||
| -laparoscopy | 430 | 91.3 | |
| -laparotomy | 37 | 7.9 | |
| -vaginal | 3 | 0.6 | |
| -combined with supravaginal uterus extirpation | 1 | 0.2 | |
| Documented complications (n) | 444 | 94.3 | |
| -no complications during surgery and/or postoperatively | 416 | 93.7 | |
| -complications | 28 | 5.9 | |
| -converted to laparotomy because of adhesions | 10 | ||
| -hematoma | 10 | ||
| -iatrogenic injury (intestine/ureter) | 3 | ||
| -incomplete removal of the ovaries | 1 | ||
| -not possible to remove ovaries because of adhesions | 1 | ||
| -other | 3 | ||
| Menopausal status (n) | 447 | ||
| -postmenopausal | 187 | 41.8 | |
| -because of hormonal breast cancer treatment | 32 | 17.1 | |
| -because of previous ovariectomy | 8 | 4.3 | |
| -premenopausal | 241 | 53.9 | |
| -perimenopausal | 19 | 4.3 | |
| -because of hormonal breast cancer treatment | 10 | 52.6 | |
| HRT in premenopausal women (n) | 217 | ||
| -postoperative usage of HRT | 97 | 45.3 | |
| Follow up (median, mo) (n = 375) | 55.8 | 0.6–169.0 | |
| -deceased in FU | 19 | 5.1 | |
| -age (median, year) | 55.5 | 43.1–72.0 | |
| -development of breast cancer in FU | 57 | 12.1 | |
| -development of PPC in FU | 1 | 0.2 | |
| -development of other malignancy | 22 | 4.7 | |
| Previous breast cancer (n) | 195 | 41.4 | |
| -age first breast cancer (median, year) | 41.0 | 24.7–64.0 | |
| Cytology | |||
| PWC sample not available | 191 | 40.6 | |
| PWC sample available | 280 | 59.4 | |
| -PWC analyzable | 257 | 91.8 | |
| -PWC malignant | 4 | 1.6 | |
| -PWC atypical | 1 | 0.4 | |
| Ascites sample reported | 21 | 4.5 | |
| -Ascites sample available for analysis | 13 | 61.9 | |
| -ascites malignant | 0 | 0 | |
| -ascites atypical | 0 | 0 | |
| Histology RRSO specimen | |||
| Ovarian (n) | 469 | ||
| -benign | 399 | 85.1 | |
| -primary serous adenocarcinoma | 4 | 0.9 | |
| -granulosa cell tumor | 1 | 0.2 | |
| -borderline tumor | 1 | 0.2 | |
| -stromal hyperplasia | 2 | 0.4 | |
| -mature cystic teratoma (benign) | 4 | 0.9 | |
| -cyst (serous/mucinous/simple/endometriosis/Theca lutein/corpus luteum) | 43 | 9.2 | |
| -cystadenoma/cystadenofibroma | 15 | 3.2 | |
| Fallopian tube (n) | 470 | ||
| -benign | 433 | 92.1 | |
| -adenocarcinoma | 5 | 0.6 | |
| -serous large cell carcinoma | 1 | 0.2 | |
| -benign mesothelial hyperplasia | 1 | 0.2 | |
| -epithelial dysplasia | 1 | 0.2 | |
| -cystadenoma/cystadenofibroma | 9 | 1.9 | |
| -endometriosis | 7 | 1.5 | |
| -endosalpingiosis | 13 | 2.8 |
